Semaglutide vs Cagrilintide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Also: AM833, NN9838
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Key Comparison Insights
- Semaglutide is FDA approved, while Cagrilintide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to Cagrilintide (Human Trials).
Detailed Comparison
| Attribute | Semaglutide | Cagrilintide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. | Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 2.4 mg weekly Once weekly |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection once weekly |
| Typical Duration | Long-term / chronic use | Long-term / chronic use expected |
| Best Time to Take | Morning, same day each week | Any consistent time weekly |
Possible Side Effects May vary by individual |
|
|
| Research Summary | STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025). | REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication. |
Frequently Asked Questions: Semaglutide vs Cagrilintide
What is the difference between Semaglutide and Cagrilintide?
Semaglutide is a weight loss peptide that a glp-1 receptor agonist with multiple fda approvals including weight loss, t2d, cv risk reduction, and kidney protection. wegovy pill approved dec 2025 as first oral glp-1 for weight loss. Cagrilintide is a weight loss peptide that a long-acting amylin analog developed by novo nordisk for obesity treatment. works through a different mechanism than glp-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. shows enhanced weight loss when combined with semaglutide (cagrisema). The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Cagrilintide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Cagrilintide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Semaglutide and Cagrilintide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.